A 4-year-old child from Delhi presents with a 5-day history of sore throat and fever. Throat culture on Loeffler's serum medium shows grey-white colonies. Gram stain reveals Gram-positive bacilli arranged in a Chinese letter pattern. Elek test is positive. The child has already received 40,000 units of diphtheria antitoxin 24 hours ago and is on penicillin V. Today, the child develops acute onset of weakness in both legs with inability to walk, and mild ptosis. What is the most appropriate next step?

Explanation

## Clinical Context This child has developed **diphtheric neuropathy** — acute ascending paralysis with cranial nerve involvement (ptosis suggests CN III/VII involvement). This complication typically appears **days 5–14** after disease onset and is caused by **both demyelination AND axonal degeneration** of peripheral and cranial nerves — a post-toxin phenomenon that is largely immune-mediated. **Key Point:** Diphtheric neuropathy occurs AFTER the acute toxin phase. By day 5, circulating free toxin has already bound to tissue; antitoxin cannot reverse bound toxin effects. The neuropathy is driven by immune-mediated nerve injury, not ongoing free toxin. ## Why Option C (Lumbar Puncture + IVIG/Plasma Exchange) Is Correct 1. **Lumbar puncture** is performed first to **rule out meningitis or Guillain-Barré syndrome** (GBS) — important differential diagnoses in a child with ascending paralysis and cranial nerve signs. CSF in diphtheric neuropathy may show albuminocytologic dissociation (similar to GBS), helping confirm the diagnosis. 2. **IVIG or plasma exchange** is the appropriate immunomodulatory therapy once contraindications are excluded: - **IVIG** (2 g/kg over 3–5 days): blocks pathogenic antibodies; first-line where available - **Plasma exchange**: removes circulating immune complexes; alternative if IVIG unavailable | Intervention | Rationale | |--------------|-----------| | **IVIG** | Polyclonal immunoglobulin modulates pathogenic immune response; first-line | | **Plasma exchange** | Removes immune complexes; alternative | | **Antitoxin (repeat)** | NOT effective — toxin already tissue-bound; neuropathy is post-toxin | | **Antibiotics** | Continue for organism eradication; do NOT treat neuropathy | **Clinical Pearl:** Ptosis + leg weakness signals **bulbar + peripheral nerve involvement** with risk of respiratory muscle paralysis. ICU monitoring and readiness for ventilatory support are essential. ## Why Each Other Option Is Wrong ### Option A: Increase Penicillin V Dose Antibiotics eradicate the organism and prevent transmission but have **no role** in treating immune-mediated neuropathy. Increasing the dose does not reverse nerve injury. ### Option B: Switch to Erythromycin Erythromycin is an alternative antibiotic for diphtheria (not for CNS penetration — this framing is incorrect). The clinical problem here is **not inadequate antibiotic coverage** but immune-mediated demyelination and axonal injury. Switching antibiotics delays appropriate immunomodulatory therapy. ### Option D: Second Dose of Antitoxin Antitoxin neutralizes only **free circulating toxin**. By day 5–10: - Toxin has already bound to nerve and cardiac tissue - Neuropathy is driven by immune-mediated mechanisms (antibody/T-cell-mediated nerve injury) - A second dose is **ineffective** and increases risk of **serum sickness** (anaphylaxis, immune complex disease) ## Key Distinction | Phase | Mechanism | Treatment | |-------|-----------|-----------| | **Acute (days 1–3)** | Free toxin → myocarditis, respiratory paralysis | Antitoxin, antibiotics, supportive care | | **Post-toxin (days 5–14)** | Immune-mediated demyelination + axonal degeneration → neuropathy | IVIG, plasma exchange, LP to exclude differentials, supportive care | **Mnemonic: POST-TOXIN = Immune** — Post-toxin neuropathy requires **Immunomodulation**, not more antitoxin. [cite: Park's Textbook of Preventive & Social Medicine 26e Ch 18; Harrison's Principles of Internal Medicine 21e Ch 143; Mandell, Douglas & Bennett's Principles of Infectious Diseases 9e]